A potential pathogenic role of interleukin-6 in a child with ANCA-negative pauci-immune crescentic glomerulonephritis: case report and literature review

Ling Hou, Lu Yin, Yubin Wu, Chengguang Zhao and Yue Du*

Abstract

Background: Crescentic glomerulonephritis is a disease characterized by severe glomerular injuries that is classified into five different pathological types. Patients with type V disease have pauci-immune crescentic glomerulonephritis (PICGN) that is negative for anti-neutrophil cytoplasmic autoantibodies (ANCAs). There are limited clinical data on the manifestations, treatment, and prognosis of type V crescentic glomerulonephritis, especially in children.

Case presentation: A 13-year-old girl who had an intermittent fever for more than 10 months was admitted to our hospital. She had no gross hematuria, oliguria, edema, or hypertension, but further tests indicated a decreased glomerular filtration rate, hematuria, proteinuria, and an elevated level of IL-6. The antinuclear antibody spectrum test was positive at 1:1000, and the ANCA and anti-glomerular basement membrane antibody tests were negative. A renal biopsy confirmed the diagnosis of ANCA-negative PICGN. We administered methylprednisolone pulse therapy with intravenous cyclophosphamide and oral mycophenolate mofetil. At the 3-month follow-up, her urine protein level was significantly lower, and her serum creatinine level was in the normal range.

Conclusions: Fever may be an extrarenal manifestation of ANCA-negative PICGN, and IL-6 may play a role in the pathogenesis of this disease. Early methylprednisolone pulse therapy with an immunosuppressant may reduce symptoms and improve prognosis.

Keywords: Anti-neutrophil cytoplasmic antibody, Pauci-immune, Crescentic glomerulonephritis, Child
often unfavorable, and more than 80% of patients progress to end-stage renal disease (ESRD) within 3 months from the onset of illness [2]. There are five types of crescentic glomerulonephritis: type I (anti-GBM disease) refers to the accumulation of antibodies against collagen in the GBM; type II refers to the deposition of immune complexes in the glomeruli; type III (pauci-immune) refers to small-vessel vasculitis due to anti-neutrophil cytoplasmic antibodies (ANCAs); type IV refers to different combinations of types I and III; and type V refers to ANCA-negative pauci-immune crescentic glomerulonephritis (PICGN) [3].

The incidence of ANCA-negative PICGN is about 14% in children with renal vasculitis, and only one-third of them have a crescentic histological pattern [4]. Published data regarding kidney involvement and prognosis are scarce. The present case report describes the successful treatment of a 13-year-old girl with ANCA-negative PICGN and reviewed previous case reports of this condition in children [5–11].

**Case presentation**

In August 2020, a 13-year-old girl was admitted to our hospital due to prolonged and intermittent fever. She first developed a fever 10 months previously that lasted for 7 days. During that time, her body temperature was elevated twice per day, reached as high as 40 °C, and was accompanied by nausea, vomiting, abdominal pain, and chills, but no rash. Subsequently, she had a fever almost once per month, lasting for about 5 to 7 days and resolving after antipyretic treatment.

Previous examinations at the local hospital (December 2019) determined her white blood cell (WBC) count was 10.18 × 10⁹/L (75.1% neutrophils), eosinophil count was normal (0.13 × 10⁹/L, reference range: 0.04 ~ 0.49 × 10⁹/L), hemoglobin was 123 g/L, platelet count was 213 × 10⁹/L, and C-reactive protein (CRP) level was 13.22 mg/L (reference range: 0 ~ 8 mg/L). Then in March 2020, a routine blood test indicated a WBC count of 7.01 × 10⁹/L (63.6% neutrophils), hemoglobin of 107 g/L, platelet count of 227 × 10⁹/L, and CRP of 79.6 mg/L. There were no microbiological tests.

She came to our hospital at that time because her fever was frequent and the duration was prolonged. She also had a history of right upper limb fractures after two falls when she was 6 and 10 years old. There were no abnormalities in her personal or family history and no abnormal signs on admission (bodyweight: 66 kg, stable from disease onset; blood pressure: 126/81 mmHg; height: 170 cm). The blood pressure in her extremities was symmetrical, and she had no abnormal vascular murmur.

Laboratory results in August 2020 (Tables 1 and 2) indicated that the WBC count and neutrophils were in the normal ranges, and the hemoglobin was slightly low. Indicators of infection and inflammation, including procalcitonin (PCT), CRP, and erythrocyte sedimentation rate (ESR), were obviously increased. We also measured the levels of multiple cytokines. The level of interleukin (IL)-6 was significantly elevated, the level of IL-10 was slightly elevated, but the levels of IL-2, IL-4, IL-17, INF-γ, and TNF were normal. Tests for mycoplasma and herpes simplex virus-IgM antibodies were positive. Screening for tumor markers, such as neuron-specific enolase (NSE) and alfa-fetoprotein (AFP), indicated no abnormalities. Bone marrow aspiration results were negative. Pulmonary computerized tomography (CT) and whole abdominal enhanced CT results indicated no apparent abnormalities, while echocardiography and subclavian artery ultrasound were also normal. We administered anti-infective therapy with ceftriaxone and azithromycin after hospitalization. After 3 days, her body temperature returned to normal, and her CRP level decreased to 40.4 mg/L.

At 2 days after admission, her serum creatinine was slightly increased at 87.9 μmol/L (reference range: 33 ~ 75 μmol/L), and 99mTc-DTPA renal dynamic imaging indicated the glomerular filtration rate (GFR) was 74.4 mL/min/1.73 m² (reduced renal function). Urinalysis indicated hematuria and proteinuria, and analysis of urinary sediment indicated 2 erythrocyte casts per HPF and 34.7 RBCs per HPF, with a dysmorphic rate of 60%. She tested positive for ANA (1:1000), but negative for anti-double-stranded DNA, anti-GBM, ANCA (PR3-ANCA, cANCA, MPO-ANCA, pANCA), and anti-phospholipase A2 receptor antibodies (PLA2R). The complement C3 and C4 levels were in the normal range, although the serum IgE was increased. Kidney ultrasound showed that both kidneys were enlarged with increased renal cortex echoes and blurred cortical and medullary boundaries.

Thereafter we performed a kidney biopsy and examined 25 glomeruli using microscopy (Fig. 1). Seven glomeruli had global sclerosis, 1 had cellular crescents, 11 had fibro cellular crescents, and 4 had fibrous crescents. The remaining glomerular aberrations were mild, with open capillary loops and no significant alterations in the mesangial area. However, the visceral and parietal epithelial cells were swollen, and Bowman’s capsule thickened and stratified. The renal tubular epithelial cells had granular degeneration, multifocal tubular atrophy (45%), the absence of tubular structures with interstitial fibrosis, and infiltration of lymphocytes and monocytes. There were no apparent changes in the arterioles. Immunofluorescence microscopy indicated 6 glomeruli had granular deposition of IgG (+) in the mesangial area and capillary wall, but the other results were negative (IgA−, IgM−, C1q−, Fb−, and C3±). Electron microscopy indicated one glomerulus had a slightly increased segmental
glomerular mesangial matrix, a small number of electron-dense regions scattered in the mesangial area, swollen podocytes and parietal epithelial cells, and a collapsed capillary basement membrane. The thickness of the GBM was normal, and there was no evidence of de- lamination, tearing, or arachnoid changes. There were also no thickened inner lighter layers of the GBM. The mitochondria of the renal tubular epithelial cells were swollen, and the endoplasmic reticulum was expanded. The basement membranes of some tubules were thick- ened, and collagen fibers and a small number of mono- cytes and lymphocytes were present in the interstitium. There were no apparent changes in the arterioles.

Our results indicated the patient had ANCA-negative PICGN. We administered 2 courses of intravenous methylprednisolone pulse therapy (500 mg/day for 3 days each), and then oral prednisone (60 mg/day) with gradual tapering. We simultaneously administered intravenous cyclophosphamide (500 mg/day for 2 days each month) and oral mycophenolate mofetil (MMF, 0.75 in the morning, 0.5 in the evening). At the 3-month follow- up (November 2020), the child’s 24-h urine protein level decreased but remained slightly elevated at 0.59 g/day (previously 1.90 g/day), her serum creatinine decreased to the normal range (42.6 μmol/L; previously 87.9 μmol/ L), and her serum albumin increased to the normal range (40.2 g/L; previously 32.6 g/L).

### Table 1 Laboratory test results at admission

| Variable          | Result | Variable          | Result | Reference range |
|-------------------|--------|-------------------|--------|-----------------|
| WBC, 10^9/L       | 8.62   | PCT, ng/mL        | 0.379  | 1.07 ~ 1.43     |
| Hb, g/L           | 102    | CRP, mg/L         | 114.00 | 4.83 ~ 10.06    |
| HCT, %            | 30.9   | ESR, mm/h         | 96     | 1.05 ~ 20.00    |
| PLT, 10^9/L       | 273    | ASO, IU/mL        | 44.7   | 0.5 ~ 20.00     |
| TP, g/L           | 66.9   | MP- IgM           | +      | 0.5 ~ 10.00     |
| ALB, g/L          | 32.6   | HSV- IgM          | +      | 1.5 ~ 4.5       |
| ALT, U/L          | 9      | HBV               | –      |                 |
| AST, U/L          | 13     | HCV               | –      | Anti-GBM Ab     |
| LDH, U/L          | 249    | HIV               | –      | PR3-ANCA        |
| T-Bil, μmol/L     | 4.8    | Ferritin, ng/mL   | 279.0  | 0.5 ~ 20.00     |
| T-Chol, mmol/L    | 4.96   | NSE, ng/mL        | 40.840 | 0.5 ~ 20.00     |
| TG, mmol/L        | 0.69   | AFP, ng/mL        | < 0.605| 0.5 ~ 20.00     |
| BUN, mmol/L       | 5.34   | VMA, mg/day       | 4.75   | 1.0 ~ 20.00     |
| Scr, μmol/L       | 87.9   | PT, s             | 11.3   | 0.5 ~ 20.00     |
| UA, μmol/L        | 323    | APTT, s           | 37     | 0.5 ~ 20.00     |
| Na, mmol/L        | 141    | Fib, g/L          | 5.1    | s.g.            |
| K, mmol/L         | 3.98   | FDP, mg/L         | 5.8    | 0.5 ~ 20.00     |
| Cl, mmol/L        | 108.5  | D-dimer, μg/L     | 691    | 0.5 ~ 20.00     |
| Ca, mmol/L        | 2.04   | IgA, g/L          | 1.32   | 0.5 ~ 20.00     |
| Glu, mmol/L       | 4.25   | IgG, g/L          | 13.90  | 0.5 ~ 20.00     |
| | | | | | Urinary protein, g/day |
| **Bold numbers** indicate a level outside the reference range |
| **WBC** White blood cells, **Hb** Hemoglobin, **HCT** Hematocrit, **PLT** Platelets, **TP** Total protein, **ALB** Albumin, **ALT** Alanine transaminase, **AST** Aspartate transaminase, **LDH** Lactate dehydrogenase, **T-Bil** Total bilirubin, **T-Chol** Total cholesterol, **TG** Triglycerides, **BUN** Blood urea nitrogen, **SCr** Serum creatinine, **UA** Uric acid, **Glu** Glucose, **PCT** Procalcitonin, **CRP** C reactive protein, **ESR** Erythrocyte sedimentation rate, **ASO** Antistreptolysin O, **MP** Mycoplasma, **HSV** Herpes simplex virus, **HBV** Hepatitis B virus, **HCV** Hepatitis C virus, **HIV** Human immunodeficiency virus, **NSE** Neuro-specific enolase, **AFP** Alpha-fetoprotein, **VMA** Vanilla mandelic acid, **PT** Prothrombin time, **APTT** Activated partial thromboplastin time, **Fib** Fibrinogen, **FDP** Fibrinogen degradation products, **ANA** Antinuclear antibody, **dsDNA** Double-stranded DNA, **GBM** Glomerular basement membrane, **ANCA** Anti-neutrophil cytoplasmic antibody, **PLA2R** Anti-phospholipase A2 receptor antibodies. s.g. Specific gravity

### Table 2 Cytokine levels at admission

| Variable          | Result | Reference range |
|-------------------|--------|-----------------|
| IL-2, pg/mL       | 1.33   | 1.07 ~ 1.43     |
| IL-4, pg/mL       | 1.13   | 1.13 ~ 1.71     |
| IL-6, pg/mL       | 40.04  | 2.15 ~ 12.75    |
| IL-10, pg/mL      | 3.44   | 1.48 ~ 2.16     |
| IL-17, pg/mL      | 3.60   | 5.06 ~ 10.06    |
| INF-γ, pg/mL      | 1.28   | 2.55 ~ 4.37     |
| TNF, pg/mL        | 1.37   | 1.05 ~ 1.95     |

**IL** Interleukin, **INF** Interferon, **TNF** Tumor necrosis factor
Discussion

This case report describes a 13-year-old girl who had a long history of intermittent fever. Due to the prolonged duration of her condition, she frequently went to the hospital but received no systematic examination or diagnosis. We admitted her 10 months after she first developed a fever and initially considered whether specific pathogens caused the fever and complicated illnesses. Although the tests for herpes simplex virus and the mycoplasma pneumonia IgM antibodies were positive, her PCT and CRP levels were significantly increased. Thus, we first considered bacterial infection and administered azithromycin with cephalosporin. Her body temperature dropped to a normal level within 3 days. However, we could not confirm a specific pathogen because of her history of repeated fever over many months. Thus, we also tested for possible tumors using bone marrow aspiration, measurement of tumor markers, and various imaging examinations, but none of the results were positive. Examination of immunological indicators of autoimmune diseases indicated that only the ANA titer was significantly increased (1:1000). This suggested possible autoimmune involvement, but the family rejected genetic testing for economic reasons.

Before treatment, the girl had no urinary system symptoms, such as gross hematuria, oliguria, edema, or hypertension. However, after admission, a systemic examination indicated hematuria and proteinuria and a mild decrease in GFR. Urinalysis is a routine test for patients with fever, urine sediment, proteinuria, and microscopic hematuria, especially when autoimmune tests are negative. She had no progressive nephritic symptoms, such as progressive oliguria or hypertension, and her urine output and blood pressure were normal. A renal biopsy and analysis of 25 glomeruli indicated that 7 glomeruli had global sclerosis, 4 had fibrous crescents, 11 had fibro cellular crescents, and 1 had cellular crescents. About 45% of the renal tubules were atrophied with interstitial fibrosis and inflammatory cell infiltration. These results confirmed the presence of a severe kidney injury. A renal biopsy is essential for guiding therapy and predicting prognosis in patients with PICG.

Fig. 1 Representative histopathologic sections from a renal biopsy of 25 glomeruli. Light microscopy (A–D) shows cellular fibrous crescents, cellular crescents and tubular atrophy, interstitial fibrosis, and massive infiltration of lymphocytes and monocytes. Electron microscopy (E) shows a slight increase of mesangial matrix and a small amount of electron density scattered in the mesangial area. A, Periodic acid Schiff (PAS) staining (400x). B, Periodic-acid silver methenamine (PASM) staining (400x). C, Masson staining (400x). D, hematoxylin-eosin staining (200x). E, electron microscopy (4000x).
N, and an early kidney biopsy provides a faster diagnosis and earlier initiation of treatment. Timely treatment of patients with active disease significantly improves short-term recovery and prognosis and is associated with disease remission. Thus, patients may recover quickly after a kidney biopsy, and a delayed diagnosis reduces the chances of successful treatment.

Because the patient had fibro-cellular and cellular crescents in 12 of 25 glomeruli and an increased level of ANA, we administrated methylprednisolone pulse therapy with cyclophosphamide and MMF. Subsequent urine protein and renal function measurements indicated significant improvements during the follow-up and no noticeable adverse reactions. The presence of crescents in the kidney biopsy suggested that there may have been repeated crescent formation. Thus, we concluded that her prolonged and repeated fever was most likely an extrarenal symptom of ANCA-negative PICGN, consistent with adult reports of ANCA-negative PICGN [12].

Previous research reported the renal survival was poorer in patients with ANCA-negative than ANCA-positive disease [12], possibly due to delayed diagnosis and less extrarenal involvement in ANCA-positive patients.

There is a low incidence of ANCA-negative PICGN in children. Shimizu et al. reported a 6-year-old girl with hematuria, proteinuria, skin rash, and arthralgia in the lower extremities [5]. She quickly progressed to renal insufficiency and required renal replacement therapy. They reported that her IL-6 was level significantly increased during the acute phase (28.4 pg/mL; their reference range: 0–4 pg/mL) but returned to the normal range after treatment. Similarly, our patient had a significantly increased level of IL-6 (40.04 pg/mL; our reference range: 2.15–12.75 pg/mL) with repeated fever, but it also returned to the normal range after treatment with cyclophosphamide and MMF. A previous report described a 76-year-old adult patient with multiple metastases from pulmonary adenosquamous carcinoma combined with ANCA-negative PICGN and an IL-6 level of 425 pg/mL (their reference range: 0–2.41 pg/mL) [13]. Another study described a 31-year-old male with seronegative pauci-immune necrotizing GN with an elevated serum IL-6 level (15.7 pg/mL; their reference range: 0–2.1 pg/mL) [14]. Our results and the results of these three previous studies suggest a possible role of the inflammatory factor IL-6 in the pathogenesis of ANCA-negative PICGN.

We also measured cytokines in children admitted to our center with diagnoses of nephrotic syndrome (NS; 114 patients) or Henoch–Schönlein purpura nephritis (HSPN; 100 patients). The levels of IL-2, IL-4, IL-10, and TNF were elevated in those with NS, and IL-17 was elevated in those with HSPN, both during the acute phase of disease. However, there was no elevation of IL-6 in patients with NS (4.37 ± 0.354 pg/mL, n = 114) or HSPN (5.79 ± 0.568 pg/mL, n = 100; Fig. 2).

IL-6 is a pleiotropic cytokine that plays a key role in regulating immune responses, inflammation, and hematopoiesis. An elevated IL-6 level also occurs in various immune diseases, such as rheumatoid arthritis and Castleman disease, and nephropathies in multiple myeloma [15]. Diabetic patients with diabetic nephropathy have higher serum IL-6 levels than those without diabetic nephropathy [16], and IL-6 participates in the pathogenesis and progression of diabetic nephropathy [17]. Lupus nephritis patients have significantly elevated levels of IL-6, and IL-6 can be used as a sensitive biomarker for disease activity and a predictor of remission in these patients [18]. IL-6 functions via classical signaling and trans-signaling, and trans-signaling plays a central role in crescentic GN in a nephrotoxic serum-induced murine model of nephritis [14]. In this animal model, the serum IL-6 level was significantly elevated, inhibition of the IL-6 pathway led to milder disease, and activation of this pathway significantly aggravated disease. In patients with ANCA-positive PICGN, IL-6 plays
an essential role in neutrophil activation, mainly due to its induction of helper T lymphocytes that can produce IL-17 [19]. However, the IL-17 level was normal in our case and in the previously described adults with pulmonary adenocarcinoma, indicating that IL-6 may not act by inducing IL-17 production in ANCA-negative PICGN. However, our results are from a single patient and do not prove a causal relationship between IL-6 and disease activity. The role and mechanism of IL-6 in ANCA-negative PICGN, therefore, needs further study.

Conclusion
We described a 13-year-old girl who was diagnosed with ANCA-negative PICGN following a long-term fever. An elevated level of IL-6 may possibly contribute to the pathogenesis of this disease. Early combined treatment with methylprednisolone pulse therapy and an immunosuppressive agent may significantly alleviate the proteinuria and improve the renal function in these patients.

Abbreviations
ANCA: Anti-neutrophil cytoplasmic autoantibodies; PICGN: Pauci-immune crescentic glomerulonephritis; RPGN: Rapidly progressive glomerulonephritis; GBM: Glomerular basement membrane; WBC: White blood cell; CRP: C-reactive protein; PCT: Procalcitonin; ESR: Erythrocyte sedimentation rate; IL: Level of interleukin; NSE: Neuron-specific enolase; AFP: Alfa-fetoprotein; CT: Computerized tomography; GFR: Glomerular filtration rate

Acknowledgments
Not applicable.

Authors’ contributions
LH reviewed the literature and contributed to manuscript writing; CGZ, YBW and LY contributed to the acquisition and analysis of the clinical data. YD, LH reviewed the literature and contributed to manuscript writing; CGZ, YBW, YD contributed to the acquisition and analysis of the clinical data. YD was responsible for revision of the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by grants from the Natural Science Foundation of Liaoning Province, China (2020-BS-116).

Availability of data and materials
The datasets used during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
Written informed consent to participate was obtained from the patient’s guardian.

Consent for publication
Written informed consent for the publication of this case report and accompanying images was obtained from the patient’s guardian.

Competing interests
The authors declare that they have no competing interests.

Received: 29 March 2021 Accepted: 17 August 2021 Published online: 23 August 2021

References
1. Anguiano L, Kain R, Anders HJ. The glomerular crescent: triggers, evolution, resolution, and implications for therapy. Curr Opin Nephrol Hypertens. 2020; 29(3):302–9. https://doi.org/10.1097/MNH.0000000000000596.
2. Prakash J, Patel PS, Prakash S, Iqbal M, Sharma SS, Singh S, et al. Etiopathological study of Crescentic glomerulonephritis and its outcome: a retrospective analysis. J Assoc Physicians India. 2019;67(11):18–21.
3. Parmar MS, Bashir K. Crescentic Glomerulonephritis. StatPearls. edn. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC; 2021.
4. Galtronri M, Consonri F, Allinovi M, Bertoli A, Jawa N, Fiasella S, et al. Prognostic factors and long-term outcome with ANCA-associated kidney Vasculitis in childhood. Clin J Am Soc Nephrol. 2021. https://doi.org/10.2215/CJN.19181220.
5. Shimizu M, Sekuguchi T, Kishi N, Goji A, Takahashi T, Kozan H, et al. A case of a 6-year-old girl with anti-neutrophil cytoplasmic autoantibody-negative pauci-immune crescentic glomerulonephritis. Clin Exp Nephrol. 2011;15(4):596–601. https://doi.org/10.1007/s10157-011-0423-3.
6. Prasad N, Agarwal N, Bhaduria D, Gupta A, Jain M. A case of psoriasis with ANCA-negative pauci-immune crescentic glomerulonephritis. Pediatr Nephrol. 2011;26(7):1173–4. https://doi.org/10.1007/s00467-011-1794-0.
7. Sethi S, Zand L, De Wiese A, Spreck U, Vana JA, Kanwar S, et al. Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. Nephrol Dial Transplant. 2017;32(suppl_1):1139–45. https://doi.org/10.1093/ndt/gfw299.
8. Malakkal JG, Hicks MJ, Michael M, Sellevski DT, Twombly K, Rheaume MN, et al. Renal survival in children with glomerulonephritis with crescents: a pediatric nephrology research consortium cohort study. J Clin Med. 2020; 9(8). https://doi.org/10.3390/jcm9082385.
9. Mayer U, Schmitz J, Bräsen JH, Pape L. Crescentic glomerulonephritis in children. Pediatr Nephrol. 2020;35(5):829–42. https://doi.org/10.1007/s00467-019-04436-y.
10. Özlu SC, Çağık A, Aydoğ˘ ˘, Bülbül M, Demircin G, Çakco E, et al. Crescentic glomerulonephritis in children: a single Centre experience. World J Pediatr. 2016;12(2):225–30. https://doi.org/10.1007/s12519-015-0036-0.
11. Sethi SK, Rana A, Bansal SB, Rana A, Yadav DK, Soni K, et al. A rare complication of pauci-immune crescentic glomerulonephritis in a child: questions. Pediatr Nephrol. 2020. https://doi.org/10.1007/s00467-020-04784-0.
12. Chen M, Yu F, Wang SX, Zou WZ, Zhao MH, Wang HY. Anti-neutrophil cytoplasmic autoantibody-negative Pauci-immune crescentic glomerulonephritis. J Am Soc Nephrol. 2007;18(2):599–605. https://doi.org/10.1681/asn.2006091021.
13. Morikawa T, Yoshida A, Kobayashi S, Shibata M, Hamada M, Kishida M, et al. AP-VAS 2012 case report: a case of ANCA-negative pauci-immune crescentic glomerulonephritis associated with IL-6-producing adenosquamous cell carcinoma of the lung. CEN Case Rep. 2013;2(11):158–64. https://doi.org/10.1177/00365513.2013.0038-1.
14. Braun GS, Nagayama Y, Maruta Y, Heymann F, van Roeyen CR, Klinkhammer BM, et al. IL-6 trans-signaling drives murine Crescentic GN. J Am Soc Nephrol. 2016;27(1):132–42. https://doi.org/10.1681/asn.2014111147.
15. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2(11):619–26. https://doi.org/10.1093/ncprheum/0338.
16. Taslıpinar A, Yaman H, Yılmaz MI, Demircin G, Sağlam M, Taslıpinar MY, et al. The relationship between inflammation, endothelial dysfunction and proteinuria in patients with diabetic nephropathy. Scand J Clin Lab Invest. 2020;80(suppl_1):i139–45. https://doi.org/10.1080/00365513.2019-04436-y.
17. Feigerllová E, Battaglia-Hsu SF. IL-6 signalling in diabetic nephropathy: from pathophysiology to therapeutic perspectives. Cytokine Growth Factor Rev. 2017;37(5–6):57–65. https://doi.org/10.1016/j.cytogfr.2017.03.003.
18. Abdel Galil SM, Ezzeldin N, El-Boshy ME. The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis. Cytokine. 2015;76(2):280–7. https://doi.org/10.1016/j.cyto.2015.05.007.
19. Abdulrahad WH, Lamprecht P, Kallenberg CG. T-helper cells as new players in ANCA-associated vasculitides. Arthritis Res Ther. 2011;13(6):236. https://doi.org/10.1186/AR3362.